Developing a vaccination evaluation model to support evidence-based decision making on national immunization programs.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Kimman, Tjeerd GBoot, Hein J
Berbers, Guy A M
Vermeer-de Bondt, Patricia E
Wit, G Ardine de
Melker, Hester E de
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
Developing a vaccination evaluation model to support evidence-based decision making on national immunization programs.Publiekssamenvatting
Among all public health provisions national immunization programs (NIPs) are beyond doubt one of the most effective in reducing mortality, morbidity, and costs associated with major infectious diseases. To maintain their success, NIPs have to modernize in response to many new and old demands regarding efficacy, safety, availability of new vaccines, emerging and evolving pathogens, waning immunity, altered epidemiological situations, and the public's trust in the program. In this paper we present an evaluation model in the form of a checklist that may help in collecting relevant scientific information that is necessary for evaluation and decision making when considering changes in a NIP. Such a checklist points to relevant information on the vaccine-preventable disease, the pathogen causing it, the vaccine, and the cost-effectiveness ratio of the vaccine. However, the final judgment on a potential change in the NIP cannot be based on a simple algorithm, as the relevant information reflects factors of a very different kind and magnitude, to which different value judgements may be added, and which may have certain degrees of uncertainty. Because any change in the NIP may be accompanied by more or less unforeseen changes in the vaccine's efficacy, evolutionary consequences, including the antigenic composition of the pathogen, and the vaccine's safety profile, an intensive surveillance program should accompany any NIP. Elements thereof include clinical-epidemiological surveillance, surveillance of vaccination coverage, immune surveillance, surveillance of microbial population dynamics, and surveillance of adverse events and safety issues. We emphasize that the decision to introduce a vaccine in the NIP should be taken as seriously, both scientifically and ethically, as the decision to withhold a vaccine from the NIP. In the latter case one might be responsible for vaccine-preventable disease and mortality.PMID
16616803ae974a485f413a2113503eed53cd6c53
10.1016/j.vaccine.2006.03.022
Scopus Count
Collections
Related articles
- Decision support in vaccination policies.
- Authors: Piso B, Wild C
- Issue date: 2009 Oct 9
- Criteria for inclusion of vaccinations in public programmes.
- Authors: Houweling H, Verweij M, Ruitenberg EJ, National Immunisation Programme Review Committee of the Health Council of the Netherlands
- Issue date: 2010 Apr 9
- Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands.
- Authors: Hubben GA, Bos JM, Glynn DM, van der Ende A, van Alphen L, Postma MJ
- Issue date: 2007 May 4
- Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
- Authors: Wisløff T, Abrahamsen TG, Bergsaker MA, Løvoll Ø, Møller P, Pedersen MK, Kristiansen IS
- Issue date: 2006 Jul 17
- The cost-effectiveness of a universal influenza vaccination program for adults aged 50-64 years in Australia.
- Authors: Newall AT, Scuffham PA, Kelly H, Harsley S, Macintyre CR
- Issue date: 2008 Apr 16